Loading...

Hemostemix

OTCPK:HMTX.F
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HMTX.F
OTCPK
CA$20M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. The last earnings update was 151 days ago. More info.


Add to Portfolio Compare Print
  • Hemostemix has significant price volatility in the past 3 months.
HMTX.F Share Price and Events
7 Day Returns
-8.4%
OTCPK:HMTX.F
-5.5%
US Biotechs
-0.8%
US Market
1 Year Returns
-30.6%
OTCPK:HMTX.F
-2.7%
US Biotechs
7%
US Market
HMTX.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Hemostemix (HMTX.F) -8.4% -11.9% -31.5% -30.6% - -
US Biotechs -5.5% -2.9% -4.6% -2.7% -2.2% 16.8%
US Market -0.8% 2.7% 7.5% 7% 37.9% 47%
1 Year Return vs Industry and Market
  • HMTX.F underperformed the Biotechs industry which returned -2.7% over the past year.
  • HMTX.F underperformed the Market in United States of America which returned 7% over the past year.
Price Volatility
HMTX.F
Industry
5yr Volatility vs Market

HMTX.F Value

 Is Hemostemix undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Hemostemix. This is due to cash flow or dividend data being unavailable. The share price is $0.0458.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Hemostemix's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Hemostemix's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:HMTX.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in CAD CA$-0.02
TSXV:HEM Share Price ** TSXV (2019-04-22) in CAD CA$0.07
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.22x
United States of America Market PE Ratio Median Figure of 3,080 Publicly-Listed Companies 18.21x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Hemostemix.

OTCPK:HMTX.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:HEM Share Price ÷ EPS (both in CAD)

= 0.07 ÷ -0.02

-3.66x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Hemostemix is loss making, we can't compare its value to the US Biotechs industry average.
  • Hemostemix is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Hemostemix's expected growth come at a high price?
Raw Data
OTCPK:HMTX.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.66x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.77x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Hemostemix, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Hemostemix's assets?
Raw Data
OTCPK:HMTX.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in CAD CA$0.01
TSXV:HEM Share Price * TSXV (2019-04-22) in CAD CA$0.07
United States of America Biotechs Industry PB Ratio Median Figure of 416 Publicly-Listed Biotechs Companies 3.26x
United States of America Market PB Ratio Median Figure of 5,186 Publicly-Listed Companies 1.91x
OTCPK:HMTX.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:HEM Share Price ÷ Book Value per Share (both in CAD)

= 0.07 ÷ 0.01

10.05x

* Primary Listing of Hemostemix.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Hemostemix is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Hemostemix's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Hemostemix has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

HMTX.F Future Performance

 How is Hemostemix expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hemostemix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Hemostemix expected to grow at an attractive rate?
  • Unable to compare Hemostemix's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Hemostemix's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Hemostemix's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:HMTX.F Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.5%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:HMTX.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:HMTX.F Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-09-30 -3 -5
2018-06-30 -2 -5
2018-03-31 -2 -4
2017-12-31 -3 -3
2017-09-30 -2 -2
2017-06-30 -3 -2
2017-03-31 -3 -2
2016-12-31 -3 -3
2016-09-30 -3 -4
2016-06-30 -3 -3
2016-03-31 -3 -4
2015-12-31 -4 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Hemostemix is high growth as no earnings estimate data is available.
  • Unable to determine if Hemostemix is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:HMTX.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Hemostemix Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:HMTX.F Past Financials Data
Date (Data in CAD Millions) EPS *
2018-09-30 -0.02
2018-06-30 -0.02
2018-03-31 -0.02
2017-12-31 -0.02
2017-09-30 -0.03
2017-06-30 -0.03
2017-03-31 -0.03
2016-12-31 -0.04
2016-09-30 -0.06
2016-06-30 -0.05
2016-03-31 -0.06
2015-12-31 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Hemostemix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Hemostemix's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Hemostemix's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Hemostemix's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Hemostemix's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Hemostemix has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

HMTX.F Past Performance

  How has Hemostemix performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Hemostemix's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Hemostemix does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Hemostemix's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Hemostemix's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Hemostemix's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Hemostemix Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:HMTX.F Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 -5.28 3.88 1.51
2018-06-30 -5.45 4.35 0.84
2018-03-31 -4.17 3.45 0.31
2017-12-31 -3.45 2.75 0.06
2017-09-30 -2.41 2.46 -0.70
2017-06-30 -2.15 2.17 -0.26
2017-03-31 -2.40 2.25 -0.04
2016-12-31 -2.73 2.44 0.18
2016-09-30 -4.09 2.70 1.28
2016-06-30 -3.46 2.21 1.19
2016-03-31 -3.78 2.43 1.30
2015-12-31 -3.99 2.45 1.49
2015-09-30 -4.94 2.88 1.56
2015-06-30 -4.85 2.75 1.54
2015-03-31 -4.82 2.41 1.82
2014-12-31 -4.33 2.19 1.56
2014-09-30 -2.52 1.20 1.19
2014-06-30 -1.99 1.00 0.90
2014-03-31 -1.50 1.08 0.37
2013-12-31 -1.54 1.22 0.29
2012-12-31 -1.67 1.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Hemostemix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Hemostemix has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Hemostemix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Hemostemix's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Hemostemix has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

HMTX.F Health

 How is Hemostemix's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Hemostemix's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Hemostemix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Hemostemix has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Hemostemix's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Hemostemix has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Hemostemix Company Filings, last reported 6 months ago.

OTCPK:HMTX.F Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 1.95 0.00 2.60
2018-06-30 3.10 0.00 3.86
2018-03-31 4.14 0.00 4.94
2017-12-31 4.84 0.00 5.21
2017-09-30 5.40 0.00 5.56
2017-06-30 -3.34 1.29 0.05
2017-03-31 -2.83 1.10 0.21
2016-12-31 -3.46 1.39 0.03
2016-09-30 -2.19 1.35 0.14
2016-06-30 -1.14 0.46 0.13
2016-03-31 -0.51 0.25 0.09
2015-12-31 0.17 0.00 0.51
2015-09-30 0.69 0.00 0.71
2015-06-30 1.63 0.00 1.75
2015-03-31 2.57 0.00 2.60
2014-12-31 3.39 0.00 3.31
2014-09-30 1.38 0.00 1.15
2014-06-30 2.20 0.00 1.85
2014-03-31 0.57 0.00 0.35
2013-12-31 0.57 0.00 0.35
2012-12-31 0.36 0.00 0.18
  • Hemostemix has no debt.
  • Hemostemix had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Hemostemix has less than a year of cash runway based on current free cash flow.
  • Hemostemix has less than a year of cash runway if free cash flow continues to reduce at historical rates of -13.3% each year.
X
Financial health checks
We assess Hemostemix's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Hemostemix has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

HMTX.F Dividends

 What is Hemostemix's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Hemostemix dividends.
If you bought $2,000 of Hemostemix shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Hemostemix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Hemostemix's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:HMTX.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 20 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Hemostemix has not reported any payouts.
  • Unable to verify if Hemostemix's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Hemostemix's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Hemostemix has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Hemostemix's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Hemostemix afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Hemostemix has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

HMTX.F Management

 What is the CEO of Hemostemix's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kyle Makofka
COMPENSATION CA$105,760
TENURE AS CEO 1.4 years
CEO Bio

Mr. Kyle Makofka Co-Founded Drive Capital Corporation in 2012 and served as its Principal. Mr. Makofka has been Chief Executive Officer at Hemostemix Inc., since November 30, 2017 and served as its President since November 30, 2017 until April 2019. He served as the Chief Restructuring Officer of Hemostemix Inc. from January 25, 2017 to November 30, 2017. Mr. Makofka served as President of Victory Rig Equipment Corporation. Mr. Makofka has over 27 years of oilfield industry experience and has worked in all facets of the oil and gas industry including field operations, dispatch, quality assurance, health and safety, marketing, supervising and manufacturing. He served as General Manager at High Arctic Energy Service Inc. He founded Victory Energy Rentals in 2004. He served as Partner of Exact Canada Industries. He served as Partner of Flame Industries. He founded Quantum Petrophysics. Mr. Makofka served as General Manager for one of Canada 's Top 50 Best Managed Companies. and Project Manager for multiple Rig Projects and Prototype Construction. Mr. Makofka was Work-over Completion Foreman for major Oil and Gas Producers and involved in various Oilfield operations from Argentina to Alaska and the Middle East. He is I.S.O. 9001/2000 Implementation Leader for major service company. Mr. Makofka's companies have been featured in Alberta Venture Magazine's Fastest Growing List and one was also a finalist for the Red Deer Chamber of Commerce Business of the Year Award. Mr. Makofka has International Well Control Certification.

CEO Compensation
  • Insufficient data for Kyle to compare compensation growth.
  • Kyle's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure of the Hemostemix management team in years:

1.2
Average Tenure
  • The average tenure for the Hemostemix management team is less than 2 years, this suggests a new team.
Management Team

Kyle Makofka

TITLE
Chief Executive Officer
COMPENSATION
CA$106K
TENURE
1.4 yrs

Kristin Gulka

TITLE
Chief Financial Officer
TENURE
1 yrs

Eilat Bain

TITLE
Director of Operations
TENURE
5.5 yrs

Alan Jacobs

TITLE
Chief Medical Consultant
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure of the Hemostemix board of directors in years:

2.3
Average Tenure
  • The average tenure for the Hemostemix board of directors is less than 3 years, this suggests a new board.
Board of Directors

Angus Jenkins

TITLE
Chairman of the Board
TENURE
2.3 yrs

Dave Wood

TITLE
Director
AGE
73
TENURE
2.3 yrs

Norman C. Wong

TITLE
Member of Scientific Advisory Board
TENURE
1.3 yrs

Don Friesen

TITLE
Director
TENURE
2.3 yrs

Kumar Hari

TITLE
Member of Scientific Advisory Board
TENURE
1.3 yrs

Alan Lumsden

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
02. Jan 19 Sell Ravi Jain Individual 02. Jan 19 02. Jan 19 -190,000 $0.06 $-11,160
01. Jan 19 Sell Ravi Jain Individual 31. Dec 18 31. Dec 18 -140,000 $0.05 $-7,455
26. Dec 18 Sell Ravi Jain Individual 24. Dec 18 24. Dec 18 -120,000 $0.01 $-732
21. Dec 18 Sell Ravi Jain Individual 21. Dec 18 21. Dec 18 -430,000 $0.06 $-26,230
25. May 18 Buy Alison Wood Individual 22. May 18 24. May 18 281,000 $0.05 $15,392
X
Management checks
We assess Hemostemix's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Hemostemix has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

HMTX.F News

Simply Wall St News

HMTX.F Company Info

Description

Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia. It is also developing various types of cells products, such as synergetic cell precursors, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.

Details
Name: Hemostemix Inc.
HMTX.F
Exchange: OTCPK
Founded:
CA$14,646,763
300,898,610
Website: http://www.hemostemix.com
Address: Hemostemix Inc.
150 - 9th Avenue SW,
Suite 1049,
Calgary,
Alberta, T2P 3H9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV HEM Common Shares TSX Venture Exchange CA CAD 21. Dec 2012
OTCPK HMTX.F Common Shares Pink Sheets LLC US USD 21. Dec 2012
TSXV HEM Common Shares TSX Venture Exchange CA CAD 21. Dec 2012
Number of employees
Current staff
Staff numbers
0
Hemostemix employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 01:00
End of day share price update: 2019/04/22 00:00
Last earnings filing: 2018/11/23
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.